85 related articles for article (PubMed ID: 2754876)
1. [Nursing of a patient with ascites being treated with OK-432].
Yamashita I; Hidaka M; Ikegawa H; Yuhara K; Mori C
Kango Gijutsu; 1989 Mar; 35(4):412-5. PubMed ID: 2754876
[No Abstract] [Full Text] [Related]
2. [Antitumor activity of neutrophils induced by a nonspecific immunopotentiator OK-432. II. Experimental study using human malignant ascites].
Umemoto T; Saji S; Oonishi A; Kunii Y; Goshima H; Tachibana S; Takao H; Tanemura H; Sakata K
Nihon Gan Chiryo Gakkai Shi; 1988 Jul; 23(7):1512-7. PubMed ID: 3183459
[No Abstract] [Full Text] [Related]
3. [TNF induction in the serum and ascites of a gastric cancer patient treated with OK-432].
Neda H; Watanabe N; Sone H; Yamauchi N; Niitsu Y; Urushizaki I
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):593-7. PubMed ID: 3954382
[TBL] [Abstract][Full Text] [Related]
4. Malignant ascites treated with streptococcal extract.
Lancet; 1983 Jun; 1(8336):1258. PubMed ID: 6134047
[No Abstract] [Full Text] [Related]
5. Advanced ovarian cancer treated by intraperitoneal immunotherapy with OK-432.
Kawagoe K; Masuda H
Jpn J Clin Oncol; 1986 Jun; 16(2):137-42. PubMed ID: 3735703
[TBL] [Abstract][Full Text] [Related]
6. [The management of malignant ascites with a streptococcal preparation, OK-432: relation between the clinical effect and auto-tumor cell killing activity by OK-432-induced ascites-derived lymphocytes].
Katano M; Yamamoto H; Mizoguchi T; Hidaka K; Hisatsugu T; Torisu M
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2464-8. PubMed ID: 3497612
[TBL] [Abstract][Full Text] [Related]
7. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction.
Katano M; Torisu M
Surgery; 1983 Mar; 93(3):365-73. PubMed ID: 6600854
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of malignant ascites. II. Immunological studies on disappearance of ascites by intraperitoneal injection of a streptococcal preparation, OK-432 (author's transl)].
Katano M
Fukuoka Igaku Zasshi; 1981 Oct; 72(10):543-55. PubMed ID: 7327499
[No Abstract] [Full Text] [Related]
9. [Treatment of malignant ascites. I. Clinical studies on intraperitoneal injection of a streptococcal preparation, OK-432 (author's transl)].
Katano M
Fukuoka Igaku Zasshi; 1981 Oct; 72(10):532-42. PubMed ID: 7327498
[No Abstract] [Full Text] [Related]
10. [Management of malignant ascites with a streptococcal preparation, OK-432: induction of growth inhibition factor(s) against tumor cells].
Katano M; Yamamoto H; Hisatsugu T
Nihon Geka Gakkai Zasshi; 1986 Apr; 87(4):471. PubMed ID: 3713694
[No Abstract] [Full Text] [Related]
11. Neutrophil-mediated tumor cell destruction in cancer ascites.
Katano M; Torisu M
Cancer; 1982 Jul; 50(1):62-8. PubMed ID: 7083126
[TBL] [Abstract][Full Text] [Related]
12. [The effect of OK-432 in the treatment of primary lung cancer].
Kishimoto T; Okada K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
[TBL] [Abstract][Full Text] [Related]
13. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.
Torisu M; Katano M; Kimura Y; Itoh H; Takesue M
Surgery; 1983 Mar; 93(3):357-64. PubMed ID: 6187080
[No Abstract] [Full Text] [Related]
14. [Picibanil (OK 432)].
Nekulová M; Mechl Z; Vorlíĉek J; Sopková B
Cas Lek Cesk; 1983 May; 122(20):632-3. PubMed ID: 6850738
[No Abstract] [Full Text] [Related]
15. Evaluation of streptococcal preparation (OK-432) local injection in patients with urinary bladder carcinoma.
Nishio S; Izeki T; Wada S; Morikawa Y; Yasumoto R; Maekawa M
Osaka City Med J; 1980; 26(1):47-59. PubMed ID: 7267092
[No Abstract] [Full Text] [Related]
16. [Antitumor activity of neutrophils induced by a nonspecific immunopotentiator OK-432. I. Experimental study using a rat model of malignant ascites].
Umemoto T; Saji S; Minatsu H; Kunii Y; Goshima H; Tachibana S; Takao H; Sakata K
Nihon Gan Chiryo Gakkai Shi; 1988 Jun; 23(6):1229-35. PubMed ID: 3230342
[No Abstract] [Full Text] [Related]
17. Neutrophil-mediated tumor cell destruction in cancer ascites. II. A OK-432 attracts killer neutrophils through activation of complement C5.
Fujimura T; Torisu M
Clin Immunol Immunopathol; 1987 May; 43(2):174-84. PubMed ID: 3105938
[TBL] [Abstract][Full Text] [Related]
18. [Whole abdominal irradiation of ovarian cancer in combined treatment with OK-432 picibanil].
Morita S; Arai T; Tsunemoto H
Gan No Rinsho; 1986 Jan; 32(1):71-5. PubMed ID: 3005691
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and experimental studies on a new intrabronchial infusion therapy of immunopotentiator-OK-432 in lung cancer].
Gose K; Hirota S; Imajo Y; Adachi S; Yonezawa K; Soejima T; Takada Y; Kimura S; Tsubota N
Nihon Gan Chiryo Gakkai Shi; 1986 Jul; 21(6):1208-16. PubMed ID: 3782973
[No Abstract] [Full Text] [Related]
20. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
